Y-mAbs Therapeutics IncNASDAQ:YMAB
- LAST PRICE11.1400
- TODAY'S CHANGE (%)-0.4500 (-3.8827%)
- Bid / Lots10.2100/ 1
- Ask / Lots11.3000/ 1
- Open / Previous Close11.6400 / 11.5900
- Day Range
- 52 Week Range
- Volume699,093
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YMAB |
|---|---|---|
| 09:32 ET | 20508 | 11.515 |
| 09:35 ET | 600 | 11.505 |
| 09:37 ET | 1000 | 11.5 |
| 09:39 ET | 5300 | 11.4901 |
| 09:42 ET | 300 | 11.48 |
| 09:44 ET | 300 | 11.43 |
| 09:46 ET | 1330 | 11.285 |
| 09:48 ET | 400 | 11.22 |
| 09:50 ET | 2040 | 11.285 |
| 09:51 ET | 2184 | 11.285 |
| 09:53 ET | 2580 | 11.21 |
| 09:55 ET | 300 | 11.21 |
| 09:57 ET | 2641 | 11.05 |
| 10:00 ET | 900 | 11.11 |
| 10:02 ET | 300 | 11.07 |
| 10:04 ET | 7649 | 11.175 |
| 10:06 ET | 300 | 11.175 |
| 10:08 ET | 1390 | 11.14 |
| 10:09 ET | 1300 | 11.09 |
| 10:11 ET | 1500 | 11.1 |
| 10:13 ET | 4313 | 11.135 |
| 10:15 ET | 3360 | 11.16 |
| 10:18 ET | 800 | 11.135 |
| 10:22 ET | 1287 | 11.04 |
| 10:24 ET | 1640 | 11.03 |
| 10:26 ET | 7479 | 10.975 |
| 10:27 ET | 1812 | 10.92 |
| 10:29 ET | 3358 | 10.885 |
| 10:31 ET | 1200 | 10.915 |
| 10:33 ET | 1100 | 10.945 |
| 10:36 ET | 900 | 10.85 |
| 10:38 ET | 2552 | 10.7101 |
| 10:40 ET | 1320 | 10.81 |
| 10:42 ET | 900 | 10.85 |
| 10:44 ET | 100 | 10.82 |
| 10:49 ET | 34879 | 10.62 |
| 10:51 ET | 1400 | 10.72 |
| 10:54 ET | 1100 | 10.687899 |
| 10:56 ET | 100 | 10.705 |
| 10:58 ET | 200 | 10.69 |
| 11:00 ET | 1044 | 10.68 |
| 11:02 ET | 600 | 10.65 |
| 11:03 ET | 200 | 10.66 |
| 11:05 ET | 1357 | 10.63 |
| 11:07 ET | 707 | 10.61 |
| 11:09 ET | 800 | 10.645 |
| 11:12 ET | 600 | 10.64 |
| 11:14 ET | 1200 | 10.61 |
| 11:16 ET | 2027 | 10.7 |
| 11:18 ET | 700 | 10.77 |
| 11:21 ET | 300 | 10.8 |
| 11:23 ET | 400 | 10.86 |
| 11:25 ET | 920 | 10.86 |
| 11:27 ET | 400 | 10.82 |
| 11:30 ET | 3326 | 10.66 |
| 11:32 ET | 630 | 10.67 |
| 11:34 ET | 23351 | 10.71 |
| 11:38 ET | 422 | 10.72 |
| 11:39 ET | 320 | 10.75 |
| 11:41 ET | 755 | 10.73 |
| 11:43 ET | 1028 | 10.72 |
| 11:45 ET | 807 | 10.75 |
| 11:48 ET | 877 | 10.69 |
| 11:50 ET | 100 | 10.695 |
| 11:54 ET | 300 | 10.65 |
| 11:56 ET | 1138 | 10.64 |
| 11:57 ET | 2000 | 10.65 |
| 11:59 ET | 2111 | 10.7 |
| 12:01 ET | 1627 | 10.84 |
| 12:03 ET | 838 | 10.81 |
| 12:06 ET | 205 | 10.86 |
| 12:08 ET | 1825 | 10.81 |
| 12:10 ET | 458 | 10.8225 |
| 12:12 ET | 2225 | 10.8416 |
| 12:14 ET | 400 | 10.87 |
| 12:15 ET | 993 | 10.93 |
| 12:17 ET | 415 | 10.97 |
| 12:19 ET | 1147 | 10.965 |
| 12:21 ET | 200 | 10.925 |
| 12:24 ET | 4500 | 10.975 |
| 12:26 ET | 1750 | 10.96 |
| 12:28 ET | 569 | 10.915 |
| 12:30 ET | 1700 | 10.915 |
| 12:32 ET | 1156 | 10.905 |
| 12:33 ET | 383 | 10.895 |
| 12:35 ET | 900 | 10.88 |
| 12:37 ET | 229 | 10.88 |
| 12:39 ET | 261 | 10.8301 |
| 12:42 ET | 1284 | 10.835 |
| 12:44 ET | 100 | 10.77 |
| 12:46 ET | 2134 | 10.78 |
| 12:48 ET | 1000 | 10.74 |
| 12:50 ET | 897 | 10.75 |
| 12:51 ET | 600 | 10.75 |
| 12:53 ET | 700 | 10.78 |
| 12:55 ET | 4088 | 10.83 |
| 12:57 ET | 106 | 10.75 |
| 01:00 ET | 615 | 10.73 |
| 01:02 ET | 600 | 10.71 |
| 01:04 ET | 200 | 10.715 |
| 01:08 ET | 1300 | 10.74 |
| 01:09 ET | 570 | 10.72 |
| 01:13 ET | 1338 | 10.725 |
| 01:15 ET | 400 | 10.73 |
| 01:18 ET | 1100 | 10.73 |
| 01:20 ET | 100 | 10.71 |
| 01:22 ET | 200 | 10.73 |
| 01:24 ET | 400 | 10.71 |
| 01:26 ET | 500 | 10.675 |
| 01:27 ET | 698 | 10.675 |
| 01:29 ET | 2000 | 10.74 |
| 01:31 ET | 2417 | 10.77 |
| 01:33 ET | 300 | 10.79 |
| 01:36 ET | 514 | 10.75 |
| 01:40 ET | 200 | 10.75 |
| 01:42 ET | 300 | 10.73 |
| 01:44 ET | 200 | 10.74 |
| 01:45 ET | 4238 | 10.73 |
| 01:47 ET | 1274 | 10.74 |
| 01:49 ET | 715 | 10.6666 |
| 01:51 ET | 300 | 10.69 |
| 01:54 ET | 240 | 10.72 |
| 01:56 ET | 300 | 10.7 |
| 01:58 ET | 200 | 10.71 |
| 02:00 ET | 977 | 10.63 |
| 02:02 ET | 694 | 10.645 |
| 02:03 ET | 102 | 10.6262 |
| 02:05 ET | 600 | 10.5951 |
| 02:07 ET | 1735 | 10.62 |
| 02:09 ET | 1443 | 10.66 |
| 02:12 ET | 300 | 10.69 |
| 02:14 ET | 300 | 10.645 |
| 02:16 ET | 427 | 10.64 |
| 02:18 ET | 1205 | 10.655 |
| 02:20 ET | 2112 | 10.735 |
| 02:21 ET | 300 | 10.735 |
| 02:23 ET | 3332 | 10.775 |
| 02:25 ET | 100 | 10.79 |
| 02:27 ET | 500 | 10.8 |
| 02:30 ET | 2313 | 10.77 |
| 02:32 ET | 6714 | 10.765 |
| 02:34 ET | 600 | 10.775 |
| 02:36 ET | 736 | 10.775 |
| 02:38 ET | 916 | 10.77 |
| 02:39 ET | 2644 | 10.795 |
| 02:41 ET | 896 | 10.83 |
| 02:43 ET | 3676 | 10.85 |
| 03:14 ET | 300 | 10.87 |
| 03:15 ET | 1819 | 10.88 |
| 03:17 ET | 11857 | 10.95 |
| 03:19 ET | 1600 | 11.01 |
| 03:21 ET | 2585 | 11.02 |
| 03:24 ET | 100 | 11.03 |
| 03:26 ET | 2134 | 11.05 |
| 03:28 ET | 800 | 11.06 |
| 03:30 ET | 2337 | 11.085 |
| 03:32 ET | 1057 | 11.1 |
| 03:33 ET | 1009 | 11.095 |
| 03:35 ET | 2001 | 11.09 |
| 03:37 ET | 1927 | 11.165 |
| 03:39 ET | 7505 | 11.16 |
| 03:42 ET | 2720 | 11.17 |
| 03:44 ET | 8029 | 11.205 |
| 03:46 ET | 2849 | 11.205 |
| 03:48 ET | 5669 | 11.22 |
| 03:50 ET | 13745 | 11.16 |
| 03:51 ET | 3715 | 11.155 |
| 03:53 ET | 18518 | 11.24 |
| 03:55 ET | 12148 | 11.25 |
| 03:57 ET | 4791 | 11.255 |
| 04:00 ET | 86972 | 11.14 |
Today
Nov 8, 2024
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments, from 6:35AM ET on Friday Nov 08, 2024 by Dow Jones
6:35AM ET on Friday Nov 08, 2024 by Dow Jones*DJ Y-mAbs Therapeutics 3Q Loss/Shr 16c >YMAB, from 6:35AM ET on Friday Nov 08, 2024 by Dow Jones
6:35AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 4, 2024
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA(R) (naxitamab-gqgk) in Japan, from 7:35AM ET on Monday Nov 04, 2024 by Dow Jones
7:35AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 25, 2024
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast, from 7:05AM ET on Friday Oct 25, 2024 by Dow Jones
7:05AM ET on Friday Oct 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Y-mAbs Therapeutics Inc | 516.6M | -20.6x | --- |
Urogen Pharma Ltd | 500.5M | -3.6x | --- |
Chromadex Corp | 550.0M | 360.3x | --- |
Grail Inc | 531.2M | -0.1x | --- |
Regenxbio Inc | 551.9M | -1.9x | --- |
Alector Inc | 480.8M | -2.4x | --- |
Company Information
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Contact Information
- Headquarters
- 230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
- Phone
- 212-847-9841
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Healy
- President, Chief Executive Officer, Director
- Michael Rossi
- Vice Chairman of the Board, Chief Business Officer
- Thomas Gad
- Chief Financial Officer, Treasurer
- Peter Pfreundschuh
- Chief Operating Officer, Senior Vice President
- Joris Wilms
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $516.6M |
|---|---|
Revenue (TTM) | $84.6M |
Shares Outstanding | 44.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-0.54 |
Book Value | $2.31 |
P/E Ratio | -20.6x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -33.66% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
